Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT05090033

Characterizing the Use of Ofatumumab in a Real World Setting

Sponsor: Novartis Pharmaceuticals

View on ClinicalTrials.gov

Summary

This is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes.

Official title: Secondary Use of Data Study Characterizing Kesimpta (Ofatumumab) Onboarding and Utilization in RMS Patients Using MSGo, With a Non-interventional Primary Use of Data Sub-study Comparing Patient Reported Outcomes Relative to Clinical Outcomes (EAFToS)

Key Details

Gender

All

Age Range

18 Years - 120 Years

Study Type

OBSERVATIONAL

Enrollment

103

Start Date

2022-12-08

Completion Date

2026-02-06

Last Updated

2026-07-31

Healthy Volunteers

No

Interventions

OTHER

ofatumumab

There is no treatment allocation. Patients administered ofatumumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Locations (7)

Novartis Investigative Site

Concord, New South Wales, Australia

Novartis Investigative Site

Southport, Queensland, Australia

Novartis Investigative Site

Clayton, Victoria, Australia

Novartis Investigative Site

Melbourne, Victoria, Australia

Novartis Investigative Site

Nedlands, Western Australia, Australia

Novartis Investigative Site

Heidelberg, Australia

Novartis Investigative Site

St Leonards, Australia